WALINGFORD: Z-Medica, LLC, a developer of hemostatic devices, announced that QuikClot Control+® approved by the FDA in June of 2017 is now commercially available.
Z-Media says “QuikClot Control+ is the first and only hemostatic dressing cleared for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding.”
QuickClot was first invented in 1984 but its acceptance by the US Military for use in the Afghanistian war made it commercially available for external wounds.
“Full commercial availability of QuikClot Control+ adds an additional life-saving tool to the arsenal of Z-Medica products that surgeons can use to help save lives and fill the unmet need of hospitals across the country,” says Z-Medica President and CEO Stephen J. Fanning. “Uncontrolled bleeding continues to be a major cause of preventable deaths. Devices like QuikClot Control+ can improve hemorrhage control, potentially savings lives and reducing healthcare costs.”
QuikClot Control+ is indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding. It may also be used to control severely bleeding wounds such as surgical wounds and traumatic injuries.